Silvia De Rubeis, PhD
- ASSOCIATE PROFESSOR | Psychiatry
Dr. De Rubeis is an Assistant Professor at the Seaver Autism Center for Research and Treatment, Department of Psychiatry, Mindich Child Health and Development Institute, and Friedman Brain Institute at the Icahn School of Medicine at Mount Sinai.
Dr. De Rubeis completed her bachelor, master, and PhD degrees in Cellular and Molecular Biology at the University of Rome Tor Vergata, Italy. During her PhD and first postdoctoral training in Dr. Claudia Bagni’s lab at the Katholieke Universiteit Leuven and Vlaams Instituut voor Biotechnologie (Belgium), she studied how the regulation of mRNA translation shapes the synaptic development in the context of Fragile X syndrome. During this training, she visited Dr. Eric Klann’s lab at the New York University as an EMBO short-term fellow. She then joined Mount Sinai for a second postdoctoral training in Dr. Joseph Buxbaum’s lab. She studied the role of rare genetic variation in autism through large-scale exome sequencing.
Dr. De Rubeis' research aims at understanding the developmental defects resulting from disruptive mutations in novel high-risk genes identified from large-scale genomic studies in autism and intellectual disability. The lab takes a genetics-first approach for functional analyses in cellular and mouse models and strives to take into account clinically relevant aspects that emerge from patient-based research.
Dr. De Rubeis is a 2020 Friedman Brain Institute Scholar Award and a 2021 Distinguished Scholar Award from the Icahn School of Medicine at Mount Sinai. She is also the recipient of a Wilhelm Bessel Research Award from the Alexander von Humboldt Foundation in 2021.
Multi-Disciplinary Training AreasDevelopment Regeneration and Stem Cells [DRS], Neuroscience [NEU]
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. De Rubeis during 2022 and/or 2023. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Other Activities: Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership.
- Autism Speaks
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.